A heveny szívinfarktus gyakoriságának és az általa okozott halálozás diurnalis és szezonális jellemzői Magyarországon

2021 ◽  
Vol 162 (14) ◽  
pp. 555-560
Author(s):  
Tamás Ferenci ◽  
András Jánosi

Összefoglaló. Bevezetés: A heveny szívinfarktus gyakoriságának és halálozásának napi és szezonális ingadozása fontos epidemiológiai adat, régóta kutatás tárgya. Célkitűzés: A szívinfarktus gyakoriságának, az általa okozott halálozásnak diurnalis és szezonális vizsgálata nagy esetszámú, válogatás nélküli betegcsoport adatainak elemzésével. Módszer: A szerzők a Nemzeti Szívinfarktus Regiszterben 2014. 01. 01. és 2017. 12. 31. között regisztrált betegek adatait dolgozták fel. Az adatok többváltozós vizsgálatára általánosított additív modelleket használtak. Eredmények: Három év alatt 30 333, ST-elevációval nem járó infarktus (NSTEMI) és 23 667, ST-elevációval járó infarktus (STEMI) miatt kezelt beteg adatait rögzítettük. A betegek utánkövetésének medián értéke 563 nap volt. Szívinfarktusra utaló panasz – mindkét infarktustípus esetén – reggel 7 és 8 óra között jelentkezett a leggyakrabban, NSTEMI esetén este 20 óra körül is találtak egy második gyakorisági csúcsot. A hét napjai a gyakoriság szempontjából szignifikáns eltérést mutattak (p<0,001): hétfőn magasabb, hétvégén lényegesen alacsonyabb incidenciát találtunk. Az éven belüli mintázat mindkét nemi, életkori és infarktustípus szerinti csoportban konzisztens: tavasszal a legmagasabb, nyáron a legalacsonyabb az incidencia (p<0,001). Az incidencia munkaszüneti napokon alacsonyabb volt (p = 0,0053 STEMI-nél, p<0,001 NSTEMI-nél). A halálozás többszempontos analízise azt igazolta, hogy a hét napjai itt is eltértek, hétvégén magasabb halálozás igazolódott (p<0,001). A munkaszüneti napoknak ugyanakkor nem volt szignifikáns hatásuk a halálozásra (p = 0,4542), és az évszakok halálozási adatai sem különböztek (p = 0,0677). Következtetés: A szívinfarktus gyakrabban fordult elő hétfőn, a reggeli órákban és az évszakok esetén tavasszal. A halálozás hétvégén nagyobb volt, mint munkanapokon. Orv Hetil. 2021; 162(14): 555–560. Summary. Introduction: Daily and seasonal variation of the incidence and mortality of acute myocardial infarction has long been the subject of research. Objective: Investigation of the diurnal and seasonal pattern of the incidence and mortality of myocardial infarction by analyzing data from a large number of consecutive patients. Method: The authors processed the data of patients registered in the Hungarian Myocardial Infarction Registry between 01. 01. 2014 and 31. 12. 2017. Generalized additive models were used for the multivariate investigation of the data. Results: 30 333 patients treated for non-ST elevation myocardial infarction (NSTEMI) and 23 667 patients with ST elevation myocardial infarction (STEMI) were recorded. The median follow-up was 563 days. Patients’ complaints most commonly occurred between 7:00 and 8:00 a.m. for both types of infarction with a secondary peak at 20:00 p.m. for NSTEMI. The days of week were significantly different (p<0.001) with a higher incidence on Monday, and lower at the weekend. The seasonal pattern was consistent in every age and sex group and according to the type of infarction: incidence was the highest in spring and the lowest in summer (p<0.001). The incidence was lower on public holidays (p = 0.0053 for STEMI, p<0.001 for NSTEMI). Multivariate analysis of mortality revealed that the days of week are significantly different here as well (p<0.001) with a higher mortality at the weekends. The effect of public holidays was non-significant (p = 0.4542) as was seasonality (p = 0.0677) in mortality. Conclusion: Myocardial infarction occurs more often in the morning hours, on Monday, and – as far as seasonal variation – in spring. The mortality at the end of the week is greater than on working days. Orv Hetil. 2021; 162(14): 555–560.

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
Y Oishi ◽  
T Shinke ◽  
H Tanaka ◽  
K Ogura ◽  
K Arai ◽  
...  

Abstract Background Recent clinical study suggests newer-generation drug-eluting stents (DES) that combine ultrathin strut and nano-coating with biodegradable polymers sirolimus-eluting stent (BP-SES) could improve long-term clinical outcomes in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) over current generation DES. However, safety profiles in very early phase have not been systematically addressed. Objective and method We exploratory investigate early vascular response following BP-SES implantation in patients with STEMI to reveal mechanism of the favorable clinical outcomes in recent studies using frequency domain-optical coherence tomography (FD-OCT). Consecutive twenty patients with STEMI who underwent FD-OCT immediately after primary PCI and were eligible for follow-up FD-OCT at 2 weeks after implantation were enrolled between June 2018 and November 2019. Results Twenty patients (age 62.7±11.3 years, male 85.0%) were enrolled with frequencies of hypertension (45.0%), diabetes mellitus (35.0%), dyslipidemia (55.0%) and smoking (80.0%). Aspiration catheter were used in all patients, and 1.13±0.34 stents were used. Only one patient (5.0%) received chronic antiplatelet therapy with aspirin prior to the onset of STEMI. All patients started to receive prasugrel as thienopyridine from this event and continued dual antiplatelet therapy for 2 weeks. The percentage of uncovered struts significantly decreased from post-procedure to 2W follow-up (69±18% post-procedure versus 30±11% at 2W follow up, p&lt;0.0001). Malapposed struts also decreased (5.6±5.7% post-procedure versus0.9±1.2% at 2W follow up, p&lt;0.0001).The average protrusion area of athero-thrombotic burden numerically decreased (0.37±0.19 at post-procedure versus 0.34±0.14 mm2 at 2W follow up, p=0.19) and its volume showed similar tendency (10.60±6.40 at post-procedure versus 9.36±5.14 mm3 at 2W follow up, p=0.19). Conclusion(s) This study firstly elucidated very early vascular responses following ultrathin strut BP-SES implantation in STEMI patients, showing early progression of strut coverage and resolution of athero-thrombotic materials. This technology may have a potential to overcome the current generation DESs in this clinical setting. Thrombus, uncovered and malapposed struts Funding Acknowledgement Type of funding source: None


Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Boniface Chan ◽  
Helen Curran ◽  
Michael P Love ◽  
Stephen Fort

Background Randomized controlled trials indicate that acute ST elevation myocardial infarction (STEMI) patients have better clinical outcomes if rapid, complete and stable coronary artery patency can be achieved. The Queen Elizabeth II Health Sciences Center in Halifax, Nova Scotia (QEIIHSC) commenced a 24 hour PPCI program in November 2005. This real world study compares 2 year mortality in STEMI patients treated by PPCI versus patients treated by fibrinolysis with provisional rescue PCI within Nova Scotia, Canada. Methods This was a single center retrospective cohort study. All consecutive Nova Scotia, fibrinolytic and PPCI eligible STEMI patients presenting within 12 hours of symptom onset between July 1 st 2005 and June 30 th 2006 treated by PPCI at the QEIIHSC or fibrinolyis outside the QEIIHSC were included. The outcome measure was all cause mortality censored on June 30 th 2007. The crude and independent association between PPCI versus fibrinolysis on mortality was estimated using a Cox regression model. Results Data for 423 eligible patients (100% of cohort) comprised of 359/423 (85%) patients treated with fibrinolytics and 64/359 (18%) treated by PPCI were analyzed. The median follow-up was 1.4 years. The median (Q25 to Q75) door to needle times in the fibrinolytic group and corresponding door to balloon times in the PPCI group were: 0.5 (.3 to .9) and 1.5 (1.1 to 1.9) hours respectively. PPCI was associated with a consistent trend toward lower mortality versus fibrinolysis during hospitalization: 2/64 (3.1%) vs. 29/359 (8.1%), P=0.16 and at 30 days 2/64 (3.1%) vs. 32/359 (15%), P=0.12. This association was significant at 1 and 2 year follow-up: 2/64 (3.1%) vs. 41/359 (11%), P=0.043 and 2/64 (3.1%) vs. 45/359 (12%), P=0.027 respectively. This corresponded with an independent HR for 2 year mortality of: 0.1 (.01 to 0.8), p=0.03. Conclusion Initial data from the PPCI program at the QEIIHSC in Halifax, Nova Scotia indicates that PPCI was associated significant reductions in mortality versus fibrinolysis for real world patients presenting with STEMI. This mortality reduction was achieved in the early pilot phase of a PPCI program with evolving door to balloon timelines versus an established fibrinolytic program with acceptable door to needle timelines.


2021 ◽  
Vol 16 (1) ◽  
pp. 1-1
Author(s):  
Charles Bloe

In this issue's ECG of the month, Charles Bloe highlights a case of a 36-year-old woman presenting with severe acute chest pain after previously being lost to follow up post ST-elevation myocardial infarction.


2019 ◽  
Author(s):  
Rui Xiang ◽  
Min Mao ◽  
Ping Tang ◽  
Jun Gu ◽  
Kanghua Ma

Abstract Background: Cysteine-rich angiogenic inducer 61 (Cyr61) is a matricellular protein participating in the angiogenesis, inflammation, and fibrotic tissue repair. Previous study has proven its value in diagnosing and risk stratification of ST-elevation myocardial infarction (STEMI). However, there is no study focusing on Cyr61 and the long-term outcome of STEMI. Methods: A total of 426 patients diagnosed with STEMI were enrolled in this study. Blood sample was acquired 24 hours after the admission. The patients were required long-term follow-up after the discharge, when primary endpoint of all-cause death and secondary endpoint of cardiac complications were observed. Cox hazard ratio model and survival analysis were used to compare the risk of patients with higher level and lower level of Cyr61. Results: We conducted an average of (48.4 ± 17.8) months of follow-up, during which a total of 28 deaths happened (6.6%), while 106 episodes of secondary endpoints occurred (24.9%). Patients with higher quartile (Q4) Cyr61 were at higher risk of death [HR 3.404 95%CI (1.574-7.360), P<0.001] when compared with lower three quartiles (Q1-Q3) Cyr61. In terms of secondary endpoints, patients with Q4 Cyr61 were subject to 4.718 [95%CI (3.189-6.978) , P<0.001] times of risk compared with Q1-Q3 Cyr61. Conclusions: For STEMI Patients, those with increased Cyr61 have higher risk of all-cause death and cardiac complications. Therefore, Cyr61 may be a useful tool in predicting the long-term prognosis of STEMI.


2018 ◽  
Vol 71 (11) ◽  
pp. A1652
Author(s):  
Christina Tiller ◽  
Hans-Josef Feistritzer ◽  
Gert Klug ◽  
Sebastian Reinstadler ◽  
Martin Reindl ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document